Recessive mutations in muscle-specific isoforms of FXR1 cause congenital multi-minicore myopathy by Estañ, M. et al.
ARTICLE
Recessive mutations in muscle-specific isoforms of
FXR1 cause congenital multi-minicore myopathy
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Mahmoud Issa 3, Carsten G. Bönnemann5, Pablo Lapunzina2,8, Grace Yoon15,16 & Victor L. Ruiz-Perez1,2,8
FXR1 is an alternatively spliced gene that encodes RNA binding proteins (FXR1P) involved in
muscle development. In contrast to other tissues, cardiac and skeletal muscle express two
FXR1P isoforms that incorporate an additional exon-15. We report that recessive mutations in
this particular exon of FXR1 cause congenital multi-minicore myopathy in humans and mice.
Additionally, we show that while Myf5-dependent depletion of all FXR1P isoforms is neonatal
lethal, mice carrying mutations in exon-15 display non-lethal myopathies which vary in
severity depending on the specific effect of each mutation on the protein.
https://doi.org/10.1038/s41467-019-08548-9 OPEN
1 Instituto de Investigaciones Biomédicas “Alberto Sols”, CSIC-UAM, 28029 Madrid, Spain. 2 CIBER de Enfermedades Raras (CIBERER), ISCIII, 28029 Madrid,
Spain. 3 Department of Clinical Genetics, Human Genetics and Genome Research Division, Centre of Excellence of Human Genetics, National Research
Centre, Cairo 12311, Egypt. 4 Departamento de Anatomía Patológica, Hospital Universitario La Paz-IdiPaz-UAM, 28046 Madrid, Spain. 5 Neuromuscular and
Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20814,
USA. 6Division of Pathology, Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8,
Canada. 7 Center for Mendelian Genomics, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Boston, MA 02115, USA.
8 Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz-IdiPaz-UAM, 28046 Madrid, Spain. 9 Bone and Joint Research Unit,
The Institution of Health Research (IIS)-Fundación Jiménez Díaz, UAM, 28040 Madrid, Spain. 10 Departamento de Anatomía, Histología y Neurociencia,
Facultad de Medicina, Universidad Autónoma de Madrid, 28029 Madrid, Spain. 11 Servicio de Genética, Hospital Ramón y Cajal, 28034 Madrid, Spain.
12 Department of Clinical and Molecular Genetics and Rare Diseases Unit, Hospital Vall d’Hebron, 08035 Barcelona, Spain. 13 Centro Andaluz de Biología del
Desarrollo (CSIC-UPO-JA), Universidad Pablo de Olavide, 41013 Sevilla, Spain. 14Department of Molecular and Human Genetics, Jan and Dan Duncan
Neurological Research Institute, Baylor College of Medicine, 1250 Moursund Street, Houston, TX 77030, USA. 15 Division of Clinical and Metabolic Genetics,
Department of Paediatrics, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, ON M5G 1X8, Canada. 16 Division of
Neurology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada. 17Present address: School of
Pharmacy and Biomedical Sciences and Curtin Health Innovation Research Institute (CHIRI), Curtin University, Perth, WA 6102, Australia. These authors
contributed equally: María Cristina Estañ, Elisa Fernández-Núñez. Correspondence and requests for materials should be addressed to
G.Y. (email: grace.yoon@utoronto.ca) or to V.L.R.-P. (email: vlruiz@iib.uam.es)
NATURE COMMUNICATIONS |          (2019) 10:797 | https://doi.org/10.1038/s41467-019-08548-9 | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
Fragile X related 1 (FXR1), fragile X related 2 (FXR2), andfragile X mental retardation 1 (FMR1), comprise a family ofhomologous genes involved in posttranscriptional mRNA
regulation. The protein products of these genes (FXR1P, FXR2P,
and FMR1P, respectively) contain KH and RGG RNA-binding
domains and have been shown to be associated with polysomal
messenger ribonucleoparticles1–4.
FXR1 is expressed in a wide variety of tissues and is subject to
alternative splicing. Accordingly, seven different FXR1 mRNA
isoforms (iso a-g) have been identified, some of which are tissue-
specific5,6. Whereas most tissues express FXR1P variants ranging
from 70 to 80 kDa, cardiac and skeletal muscle only generate
FXR1P isoforms of 82 and 84 kDa (iso-e/f; P82,84), which contain
an additional 81-nucleotide exon (exon-15) exclusive to these
variants5–8. Testis is considered an exception since most FXR1P
isoforms, including those carrying exon-15 were reported in this
organ9. The incorporation of exon-15 into the P82,84 variants
leads to the in frame insertion of 27 extra amino acids encom-
passing an arginine-rich motif that is also present in FXR2P, and
is similar to the nucleolar localization signal of the HIV1-REV
protein10. Both the distinctive splicing of exon-15 in muscle tis-
sues and its corresponding amino acid sequence are conserved
throughout vertebrate evolution11,12. However, expression of
FXR1P proteins is not uniform among all cells of the myogenic
lineage. During muscle differentiation, myoblasts synthesize all
FXR1P isoforms, while myotubes only express P82,84 variants,
although at higher proportion than their precursor cells5,7,8.
Constitutive inactivation of Fxr1 in mice was reported to cause
neonatal lethality most probably due to cardiac and/or respiratory
failure secondary to loss of architectural structure of myofibers13.
In the same manner, knockdown of Fxr1 resulted in muscle-
specific defects in Xenopus and abnormal cardiac and striated
muscle development in zebrafish12,14. Muscle cells from patients
with facioscapulohumeral muscular dystrophy were also descri-
bed with decreased P82,84 levels7. However, no human disease
has previously been demonstrated to be associated with FXR1
mutations. Herein, we report that recessive mutations in exon-15
of FXR1 cause musculoskeletal defects of variable severity in
humans and mice.
Results
Clinical evaluation. Patients from two unrelated families were
included in this study. The proband of family 1 was a 2.5-month-
old Egyptian male, the second child of healthy first cousin par-
ents. During pregnancy, reduced fetal movement was noted and
serial ultrasound revealed oligohydramnios. This patient pre-
sented at birth with severe hypotonia, shallow breathing, episodes
of tachycardia and fractures of the humeri and femora. On
examination, he also had areflexia, tongue fasciculations, hypo-
plastic genitalia and cryptorchidism. Neurologically, the motor
power was grade 1 (complete absence of movement). Brain CT
and echocardiography were normal. The baby died at the age of
five months. Medical termination of a subsequent pregnancy was
conducted due to lack of fetal movement suggestive of the same
condition. The affected status of this fetus (V-4) was subsequently
clinically confirmed. Family history also included a similarly
affected female sibling who died at the age of 70 days (Fig. 1a–c).
MLPA of SMN1/2 in the proband excluded spinal muscular
atrophy.
Patients from family 2 were three siblings with proximal
muscle weakness, aged 28, 26, and 24 years, born to non-
consanguineous parents. All three initially presented with
neonatal hypotonia and delayed gross motor milestones (Fig. 1d).
They also had moderate (II-3) or mild (II-4,-5) obstructive sleep
apnea. The eldest sibling was additionally noted to have
cryptorchidism, short stature, obesity and mild scoliosis (13
degrees). All three siblings had normal cardiac and cognitive
function. Mild progression of their muscle weakness occurred
over the past five years, but all are independent with respect to
activities of daily living, including ambulation. In all siblings
electromyogram revealed low amplitudes and nerve conduction
studies were normal, suggestive of a myopathic process. Detailed
clinical information of families 1 and 2 is available as
Supplemental Data.
Muscular pathology of patients from family 2. Histopatholo-
gical analysis of muscle biopsy from II-4 revealed fatty infiltration
and muscle fibers with increased central nuclei and striking type I
fiber predominance (Fig. 1e–g). There was no fiber necrosis,
regeneration or inflammatory infiltrates. Multiple small core
lesions were detected within many muscle fibers which, by
transmission electron microscopy (TEM), appeared as focal dis-
ruptions in the myofibrillar striation pattern, with Z-band
streaming and absence of mitochondria. Cores were typically
one to two sarcomeres in length (Fig. 1h). Muscle MRI for II-5
revealed extensive fatty atrophy of the anterior and posterior
muscle groups.
FXR1 exon-15 is mutated in patients with recessive congenital
myopathy. To identify the underlying genetic defect in the pro-
band of family 1 we used homozygosity mapping and whole-
exome sequencing (WES). Based on parental consanguinity,
variants were filtered according to a recessive model of inheri-
tance assuming a homozygous mutation by descent. This revealed
a four-nucleotide deletion at the 3′-end of exon-15 of FXR1
(XM_005247813.3: c.1764_1767delACAG (delACAG)) which
was prioritized as candidate due to the role of FXR1 in muscle
development (Supplementary Table 1a,b). The four-nucleotide
deletion causes a frameshift predicted to replace the last 90 amino
acids of the muscle FXR1P isoforms (iso-e/f; P82,84) with 36 new
residues (p.Arg588Serfs*37). Since the premature stop codon
generated by this variant remains in the last exon of the gene, the
corresponding mutant iso-e/f transcripts escape nonsense medi-
ated mRNA decay (NMD) degradation15 (Supplementary
Fig. 1a). The delACAG variant was absent from population
databases (gnomAD, ExaC, EVS, and 1000G) and was confirmed
to be homozygous in the proband and in the affected fetus (V-4)
by Sanger sequencing, while both parents were heterozygous
(Fig. 1a). No DNA was available from the deceased sibling V-2.
Consistent with parental consanguinity, the FXR1 variant was
embedded within large chromosomal segments of homozygosity
in the proband (54.6 Mb) and V-4 (23.7 Mb) (Supplementary
Fig. 2a).
In family 2 we applied WES to four members of the family (the
three affected siblings and the mother), which revealed a
homozygous single nucleotide deletion also in exon-15 of FXR1
(XM_005247813.3: c.1707delA (delA); p.Lys569Asnfs*57) in all
three affected siblings. The homozygous variant was validated by
Sanger sequencing in II-3, II-4, and II-5 and the asymptomatic
mother was confirmed to be a heterozygous carrier of the
mutation (Fig. 1d). Even though the parents were apparently
unrelated, the three affected siblings resulted to be homozygous
for a 5.98 Mb region comprising FXR1 by SNP-array hybridiza-
tion. Deletion of this region in the paternal allele was excluded
following assessment of the SNP-array log-R ratio plots and by
aCGH (Supplementary Fig. 2b, c).The c.1707delA deletion causes
the same shift in reading frame as the c.1764_1767delACAG
variant. However, c.1707delA is located at the 5′-end of exon-15,
and thus the predicted P82,84 isoforms lack most exon-15-
specific amino acids, (Supplementary Fig. 1a, c, d). Variants of
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genes that are known to cause multi-minicore myopathy and
could act as potential genetic modifiers, identified in both families
with allele frequencies less than 0.1, are indicated in Supplemen-
tary Table 2.
DelACAG P82,84 variants localize to cytoplasmic granules. To
study the effect of the delACAG mutation on FXR1P proteins, we
isolated primary myoblasts from V-4 and checked FXR1P
expression in these cells before and after differentiation into
myotubes. As predicted, western blot (WB) analysis demon-
strated that V-4 cells synthetize P82,84 proteins of lower mole-
cular weight. However, unlike control cultures, these variants
were predominantly detected in the non-soluble fraction of both
myoblast and myotube lysates. On the contrary, expression of
P70-80 isoforms was normal in cell extracts from V-4 myoblasts
(Fig. 2a and Supplementary Fig. 3). Consistent with this, the
P82,84 isoforms from V-4 myotubes were localized in ring-
shaped cytoplasmic granules by anti-FXR1P immuno-
fluorescence, while in the corresponding control cells, the wild
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type (wt) P82,84 proteins were uniformly distributed throughout
the entire cytoplasm. Anti-FXR1P staining in myoblasts, which
generate less amount of P82,84, revealed similar cytosolic dis-
tribution of FXR1P isoforms in V-4 and control cells, except for a
small number of FXR1P granules in some V-4 myoblasts
(Fig. 2b). No differences in levels of FXR1P isoforms were
observed between patient and control primary fibroblasts (Sup-
plementary Fig. 3).
Myf5-dependent inactivation of Fxr1 is lethal in mice. Con-
stitutive ablation of all FXR1P isoforms in mice due to Fxr1 exon-
1 deletion was previously shown to be neonatal lethal13. Although
not definitive, this phenotype was attributed to skeletal and/or
cardiac muscular defects. To investigate this further we generated
tissue-specific knockout mice in which the entire repertoire of
FXR1P isoforms was primarily inactivated in skeletal muscle. This
was accomplished by mating Fxr1cko/cko floxed mice carrying the
first exon of Fxr1 flanked by LoxP sites to Myf5-Cre transgenic
mice (B195AP-Cre)16 that were made heterozygous for a con-
stitutively inactivated Fxr1 allele lacking exon-1 (Myf5-Cre+/−;
Fxr1+/ko). Myf5 codes for the earliest myogenic transcription
factor that directs progenitor cells to differentiate into the skeletal
muscle lineage and is involved in myoblast specification17,18.
Evaluation of litters from these crosses at P0-1 identified 19%
neonatal lethality with the large majority of non-surviving new-
born mice having the Fxr1ko/cko;Myf5-Cre+/− genotype (87.5%).
In contrast, only 1.51% of all living pups showed this allelic
combination (Fig. 3a and Supplementary Fig. 4a, b). Specific
ablation of FXR1P in skeletal muscle of Fxr1ko/cko;Myf5-Cre+/−
mice was confirmed by WB using extracts from several tissues of
E18.5 mice (Supplementary Fig. 4c, d). Hence, loss of the com-
plete collection of FXR1P isoforms in the skeletal myogenic
lineage alone is sufficient to cause neonatal lethality.
Mice with exon-15 mutations display myopathic phenotypes.
We replicated the delACAG variant in mice by CRISPR-Cas9
genomic editing. Human and mouse FXR1 are 95% identical at
the DNA level and the corresponding delACAG deletion in the
mouse (NM_001113188.1:c.1764_1767delACAG; p.(Arg588-
Serfs*37) also result in the substitution of the last 90 amino acids
of the murine iso-e/f by the same 36 extra amino acids of the
mutant protein of family 1. In parallel, another mouse line har-
boring a different exon-15 mutation consisting of one nucleotide
duplication was generated during genomic editing
(NM_001113188.1:c.1766dupA). The new frameshift resulting
from this allele runs into a premature termination codon 10
triplets downstream within exon-16 (p.Pro590Alafs*10) and is
predicted to undergo NMD (Supplementary Fig. 1).
Homozygous mutants of the two CRISPR lines were born at
Mendelian ratio and survived to adulthood, but developed a
muscular phenotype which was more severe in delACAG mice.
On gross observation, delACAG homozygotes (delACAG) were
leaner than their littermates and exhibited lower body weight
than their corresponding sex-matched and age-matched wt
controls (mean body weight reduction of delACAG females at
age 6, 9, and 12 weeks: −15.56%, −20.94%, and −16.43%,
respectively). No phenotype was observed in delACAG hetero-
zygous mice. Homozygous dupA mutants (dupA) were macro-
scopically indistinguishable from their littermates, but also had
decreased body weight compared to controls (mean body weight
reduction of dupA females aged 6, 9, and 12 weeks: −2.53%,
−7.58%, and −6.97%, respectively) (Fig. 3b, c). Following
dissection of hindlimbs and gastrocnemius, it became apparent
that delACAG mutants had reduced muscle mass (Fig. 3d). The
muscle phenotypes of delACAG and dupA mice were confirmed
by MRI of hindlimbs of 14-week-old female mice (Fig. 3e and
Supplementary Fig. 4e). Additionally, we evaluated muscle
strength in both exon-15 mutants by comparing the weightlifting
capacity of mice and by the hanging wire test, while sustained
rotarod exercise was used to measure fatigue resistance. In all
tests, delACAG mice scored significantly lower than their wt
littermates, while dupA mice performed similarly or slightly less
well than controls (Fig. 3f, g and Supplementary Fig. 4f).
Bone mineral density is decreased in delACAG mice. Bone
mineral density (BMD) was assessed in both CRISPR mouse
models using DXA. BMD calculated both at the femur and at the
lumbar vertebrae resulted to be significantly lower in delACAG
mutants compared to their wt littermates. Milder BMD differ-
ences between dupA and control mice were also observed, but
were not statistically significant (Fig. 3h). Radiographs of dis-
sected mouse limbs additionally demonstrated decreased BMD in
delACAG mice (Fig. 3i and Supplementary Fig. 4g).
Multicore myopathy in mice carrying exon-15 mutations. We
performed histological characterization of murine delACAG and
dupA muscles using transverse frozen sections of vastus lateralis/
gastrocnemius/soleus. H–E staining revealed reduced fiber size,
increased cell density (cells/area) and increased central nuclei in
mutant mice, with the severity of these defects being greater in
delACAG homozygotes. The average length of minimal Feret’s
diameter (MFD) determined in the vastus lateralis was reduced
by 41.56% in delACAG mutants and 23.11% in dupA mice, and
the percentage of fibers with central nuclei in the same muscle
was 31.87% and 13.41% in delACAG and dupA mutants,
respectively. NADH-TR histochemistry identified areas with no
enzymatic activity (cores) in multiple delACAG fibers, while
cores were very sporadically detected in dupA mice. Lastly,
ATPase histoenzymatic staining (pH 4.3) revealed predominance
of type I fibers in both mutants, especially in delACAG mice.
Fig. 1 Clinical features and mutations. a Pedigree of Family 1 showing the proband (arrow), similarly affected older female sibling and affected fetus. DNA-
sequencing chromatograms demonstrate a homozygous four nucleotide deletion at the 3′-end of FXR1 exon-15 in the proband, which is in the heterozygous
state in his mother (carrier). Carrier chromatogram shows normal (top) and mutant (underneath) nucleotide sequences. b Proband of family 1 at the age of
2.5 months with inserted Ryle tube for feeding, short neck, short hands and digits, lateral rotation of right upper and lower limbs and medial rotation of left
upper and lower limbs due to severe hypotonia. The picture also shows bilateral low inserted thumbs with dorsi-flexion of both feet, no obvious
demarcation of large joints with transverse crease on the left knee and ankles and genital hypoplasia. c X-rays (AP view) showing bilateral mid fractures of
humeri (upper panel, arrow) and femora (lower panel, arrow). d Pedigree of family 2 and DNA-sequencing chromatograms corresponding to the 5′-end of
FXR1 exon-15 of the mother (carrier) and one of the affected siblings showing a single adenine deletion from a run of eight-adenines in the homozygous
state in the patient. The father was not available for carrier testing. Only nucleotide sequence of the wt allele is written on the chromatogram of the mother.
e–h Representative photomicrographs of H-E staining. Scale bar 60 µm (e), Masson trichrome staining. Scale bar 500 µm (f), ATPase pH4.3
histochemistry. Scale bar 200 µm (g), and TEM. Scale bar 10 µm (h) from a right triceps biopsy of individual II-4 of family 2. Arrows indicate internalized
nuclei, fatty infiltration, and areas of Z-streaming and minicores in e, f and h, respectively. Different fibers in TEM images are numbered
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Relative frequency of type I fibers in the soleus was 43.3% in wt,
90.4% in delACAG and 53.3% in dupA mutants (Fig. 4a–e).
Muscle fibers from the gastrocnemius of exon-15 mutants and
control mice were analyzed by TEM. Consistent with NADH-TR
staining, the predominant pathological feature of delACAG fibers
consisted of intracellular regions of variable size characterized by
disintegration of Z-band and sarcomere structure (cores).
Ultrastructurally, the appearance of delACAG fibers ranged from
mildly affected fibers containing only several regions of
Z-streaming to highly disorganized cells with a large core
spread over nearly the entire fiber section. Misalignment,
irregular shortening, broadening and zig-zagging of Z-lines
were observed in zones with preservation of sarcomeres. In
addition, abnormal accumulations of mitochondria and central
nuclei were detected. TEM analysis of dupA fibers showed
abnormalities similar to those observed in delACAG mice with
respect to the appearance of Z-lines and there were occasional
small areas of Z-streaming. Cores were not detected suggesting
that they are infrequent in these mice (Fig. 4f, g and
Supplementary Fig. 5a, b).
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Fig. 2 Expression and localization of FXR1P isoforms in family 1. a Representative anti-FXR1P immunoblots of soluble (SF) and insoluble (IF) fractions of
protein extracts from control and V-4 myoblasts and myotubes, n= 5. An antibody against all FXR1P isoforms (Proteintech) and another one specific for
iso-e/f (#27-15) were used in left and right panels, respectively. Numbered brackets on left panel designate P70-80 FXR1P isoforms (1), and P82,84
isoforms (2). Asterisks indicate a non-specific band. α-actinin and α-tubulin were used as loading controls. b Anti-FXR1P immunofluorescence showing
subcellular distribution of FXR1P in control and V-4 myoblasts and myotubes, n= 5. Scale bar 15 µm. Arrows in V-4 myoblasts and myotubes point to ring-
shaped granular accumulations of mutant P82,84 isoforms. The granule magnified in V-4 myotubes is indicated with an arrowhead (scale bar 2 µm).
Desmin and MHC were used as myogenic markers with MHC being an indicator of myotube differentiation. Nuclei are stained with DAPI
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Expression and localization of P82,84 in exon-15 mutants. To
understand the phenotypic differences between delACAG and
dupA mice, we studied Fxr1 expression both at the mRNA and
protein levels in skeletal muscle of these mutants. In keeping with
the dupA transcript being subjected to NMD, qRT-PCR analysis
showed that the levels of Fxr1 mRNA in dupA mice were reduced
to 30.9% of control levels. The same experiment in delACAG
mice revealed a milder reduction of the Fxr1 transcript to 74.7%
of control levels (Fig. 5a and Supplementary Fig. 6). Since the
delACAG mutation should not trigger NMD, this data could
indicate the disruption of a positive feedback mechanism. Muscle
expression of FXR1P proteins was analyzed by immunoblotting.
This demonstrated a marked decrease in the levels of FXR1P
isoforms in dupA mice, with just a faint band corresponding to
the dupA P82,84 molecular weight detectable in the soluble
fraction of muscle extracts. In delACAG mice the quantity of
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P82,84 appeared not to be substantially diminished but, as in V-4
myotubes, these variants were principally localized in the non-
soluble part of muscular lysates (Fig. 5b). The same results were
observed on WB of primary myogenic cultures from these mice
(Supplementary Fig. 7a). Subsequently, we used confocal micro-
scopy in isolated fibers from the extensor digitorum longus (EDL)
to ascertain the subcellular localization of normal and mutant
P82,84 isoforms. FXR1P immunofluorescence identified the wt
P82,84 in a striped pattern perpendicular to the main axis of the
fiber. This staining was strongly reduced in dupA fibers, while in
delACAG fibers, similar to V-4 myotubes, the FXR1P proteins
were detected in cytoplasmic granules of variable dimensions
(Fig. 5c). Immunofluorescence analysis of mouse primary cultures
showed dispersed cytoplasmic distribution of FXR1P isoforms in
all genotypes at the myoblast stage with presence of ring-shaped
V-4-like granules exclusively in delACAG cultures. Following
differentiation, FXR1P expression was essentially absent in dupA
myotubes and was restricted to ring-shaped aggregates in delA-
CAG differentiated cells (Supplementary Fig. 7b, c).
Subcellular distribution of P82,84 in mouse striated muscle has
previously been described as a dot-like pattern reminiscent of
costameres associated with Z-bands, but robust co-localization
analysis had not been performed5,12,13. To refine the localization
of normal P82,84 isoforms and to compare it with that of the
mutant proteins we conducted double-immunostaining experi-
ments using recognized sarcomere markers. Co-
immunofluorescence of FXR1P with α-actinin or phalloidin to
visualize Z and M lines showed the wt FXR1P isoforms in a
position immediately adjacent to Z-lines. Consistently, double-
immunostaining of FXR1P with RYR and COX-IV, as markers
for triads (T-tubule+ sarcoplasmic reticulum (SR)) and mito-
chondria, respectively, identified the P82,84 wt proteins between
the two triads that flank each Z-line, and partially overlapping
with mitochondria. Subcellular localization of the remaining
P82,84 isoforms in dupA fibers was comparable to the wt
proteins, while the FXR1P signal was almost absent from Z-lines
in delACAG fibers (Fig. 6). Anti-COX-IV immunofluorescence
demonstrated both mitochondrial accumulations and areas
deprived of mitochondria (cores) in delACAG fibers, with a
proportion of P82,84 granules overlapping or placed near
mitochondrial groupings. Fewer accumulations of mitochondria
were detected in dupA fibers (Fig. 6b and Supplementary Fig. 8a).
Next, we examined ultrathin sections of murine gastrocnemius
by TEM to search for delACAG granules. We identified a series
of non-membranous globular/ring-shaped cytoplasmic struc-
tures of heterogeneous size in delACAG mutants, but not in wt
or dupA mice (Fig. 7a). TEM analysis of V-4 and control
differentiated myotubes at the EM level also revealed similar type
of granular structures in patient cells (Fig. 7b). Ultrastructurally,
delACAG granules were composed of a highly electrodense
external layer encircling a different kind of material. Both,
TEM and confocal FXR1P-positive granular structures had
similar diameter length distribution (mean MFD: 0.51 µm
(TEM) and 0.59 µm (confocal)) and were often found next to
mitochondria (Fig. 7a and Supplementary Fig. 8b). Immunogold
labeling of FXR1P on gastrocnemius sections conclusively
identified the mutant protein in the outer electrodense layer of
delACAG granules (Fig. 7c, d). Immunofluorescence and
TEM analysis of fibers from wt/delACAG heterozygotes
detected similar granular structures, although in a
much smaller number than in delACAG homozygotes (Fig. 5c
and Supplementary Fig. 8c). In contrast, as in dupA mice, no
FXR1P granules were observed by TEM in the muscle biopsy of
family 2.
DelACAG granules contain polyA-mRNA but differ from SGs.
Since delACAG FXR1P isoforms maintain all the RNA binding
motifs of the wt protein, we investigated whether they could
interact with polyA-mRNA. We conducted fluorescence in situ
hybridization (FISH) in isolated EDL mouse fibers and V-4
myotubes using a Cy3-labeled oligo-dT probe and observed that a
proportion of delACAG granules, commonly the bulkiest, were
positive for oligo-dT hybridization. In contrast, no signal was
obtained with a similarly labeled control probe consisting of a
scrambled nucleotide sequence with no specific target19. Thus,
delACAG granules incorporate mRNA (Fig. 8 and Supplementary
Fig. 9).
Consequently, we analyzed if delACAG accumulations could
function as stress granules (SGs) given that FXR1P is a
component of these structures20. SGs are RNA-protein aggregates
triggered by cellular stress that stall mRNA translation21,22. To
test this hypothesis, we co-immunostained V-4 and control
myoblasts with FXR1P and the SG markers TIAR and
FXR2P20,23. Myoblasts were cultured in differentiation media
for one day to promote iso-e/f expression and subsequently
maintained untreated or stressed with arsenite (ARS). Complete
staining overlap between FXR1P and TIAR or FXR2P was
observed in ARS-induced amorphous granules corresponding to
SGs, both in control and patient myoblasts. However, there was
only faint or no co-localization between FXR1P and SG markers
in characteristic ring-shaped delACAG granules. Co-
immunostaining of delACAG particles with processing bodies
(P-bodies), which are a different type of RNA-protein aggregates
involved in mRNA degradation21,22 was also examined. This was
achieved by FXR1P and RCK double immunolabelling, with RCK
being a marker for both P-bodies and SGs24. Again, no-co-
localization was observed between FXR1P and RCK at ring-
shaped delACAG granules indicating that they are not P-bodies
(Fig. 9a, b).
Fig. 3 Phenotype of mice with different Fxr1 mutations. a Percentage (%) of neonatal lethality at P0-1 in offspring (n= 82) from crosses between
Myf5-Cre+/−;Fxr1+/ko males and Fxr1cko/cko females. Genotypes for Fxr1 and Myf5-Cre are indicated in the X-axis. Presence or absence of Myf5-Cre is
indicated with + and – symbols. b Growth chart of homozygous delACAG and dupA mice compared to wild type controls (wt) and wt/delACAG
heterozygotes. Female mice were weighed weekly after weaning from week 4 to 12. n= 16(wt), 13(wt/delACAG heterozygotes), 12(delACAG), 9(dupA).
Data are mean ± s.e.m. followed by two-tailed unpaired Student’s t-test. c Representative image of three months old delACAG, wt and dupA female mice.
d Representative images of left hindlimb (top panel) and gastrocnemius (bottom panel) from delACAG and dupA mutants compared to their respective wt
littermates (3-month old female mice). Scale bar 1 cm. eMuscle volume corresponding to a segment of hindlimbs determined by MRI (14 weeks-old female
mice), n= 4(wt), 9(delACAG), 4(dupA). Data are mean ± s.d. followed by one-way ANOVA (***) with Tukey post-hoc test. f Score values for weight test
(14 weeks-old female mice, n= 6(wt), 7(delACAG), 7(dupA)). Data are mean ± s.d. followed by one-way ANOVA (***) with Tukey post-hoc test.
g Cumulative number of falls during rotarod endurance test (14 weeks-old female mice), n= 4(wt), 5(delACAG), 4(dupA). Data are mean ± s.e.m.
followed by one-way ANOVA (**) with Tukey post-hoc test. h BMD calculated by DXA at the spine and the right femur of 4 months old female mice, n= 4
(wt), 4(delACAG), 3(dupA). Data are mean ± s.d. followed by one-way ANOVA (**) with Tukey post-hoc test. i Representative X-Ray image
corresponding to dissected left hindlimbs from delACAG and wt littermates (4 months-old female mice), n= 4(wt), 1(wt/delACAG), 8(delACAG), 4
(dupA)
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Mutant iso-e variants assemble into delACAG granules in
HeLa. We checked if delACAG granules can assemble outside of
a myogenic environment, by transfecting HeLa with N-terminally
EGFP tagged human iso-e constructs carrying either wt sequence
or the delACAG, delA or dupA mutations. Expression of all
fusion proteins was validated by WB in HEK293T
(Supplementary Fig. 10a, b). Moreover, to evaluate the involve-
ment of iso-e in SGs, we treated the transfected HeLa with or
without ARS and analyzed the expression of EGFP and SG
markers, including TIAR, FXR2P and FMR1P20. Robust co-
localization between wt iso-e and SG markers was observed in
ARS-treated cells, thus proving that this isoform is recruited into
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SGs. In untreated cells, wt iso-e was found disseminated in the
cytoplasm, although we noted a variable proportion of stressed
cells, (owing to transfection or FXR1P overexpression) with iso-e
in SGs. However, independent of ARS treatment, all three mutant
iso-e proteins (delACAG, delA, and dupA) were located in
cytoplasmic granules either as part of amorphous SGs or
assembled into delACAG-like ring-shaped aggregates (Fig. 9c and
Supplementary Fig. 10c). HeLa delACAG-like granules exhibited
no overt co-localization with TIAR or FMR1P, and only a few had
faint positive co-localization with FXR2P (Supplementary
Fig. 11). As the extra C-terminal amino acids incorporated after
the dupA mutation differ from those added by the delA/delA-
CAG mutations (Supplementary Fig. 1d), the accumulation of
mutant iso-e into delACAG-like granules in HeLa does not
depend on a specific C-terminal amino acid sequence. Absence of
granules in dupA mice and in the muscle biopsy of family 2 is
likely due to low expression levels of the corresponding P82,84 as
demonstrated in muscle tissue of dupA mice. No biological
material was available from family 2 to test this hypothesis.
Expression profiling of delACAG skeletal muscle. To investigate
the molecular processes disrupted in delACAG mice we con-
ducted comparative RNA-Seq-based transcriptome analysis of
delACAG and control muscles using RNA from gastrocnemius+
soleus of P15 mice. Following data normalization 233 differen-
tially expressed genes (DEGs) were selected of which 150 were
upregulated and 83 downregulated in the mutant mice. Selected
DEGs had fold changes ≥1.9 or ≤−1.9 (p-adjusted value ≤ 0.05).
Gene ontology (GO) functional enrichment analysis of these
transcripts yielded 25 GO annotations including p53 signaling,
G1/S cell cycle transition, DNA damage response; apoptosis,
muscle-development, muscle-differentiation, and muscle-con-
traction, protein kinase B signaling, action potential and mem-
brane depolarization (Fig. 10a–c and Supplementary Table 3a).
Moreover, within the nominated DEGs we recognized known
proinflammatory genes. KEGG enrichment analysis also identi-
fied p53 signaling as the most statistically significant pathway
(Supplementary Table 3b). RNAseq results of representative
genes were verified in gastrocnemius from delACAG mice by
qRT-PCR, using Tbp and Gusb as reference genes, or WB ana-
lysis. In these experiments age-matched dupA mice were included
for comparison (Fig. 10d–f and Supplementary Fig. 12). Quan-
tification of the expression of the p53/p63/p73 gene family by
qRT-PCR revealed a remarkable induction in the levels of Trp73
mRNA and to a lesser degree of the Trp63 transcript in delACAG
mice (Fig. 10d and Supplementary Fig. 12a). In contrast, two
TaqMan assays showed no significant changes in Trp53 mRNA
levels. Similarly, we confirmed upregulation in delACAG mutants
of the following transcripts: (i) the cell cycle regulator Cdkn1a (ii)
the proinflammatory/proapoptotic related transcripts Nfkb2,
Eda2r, Bex1, Cxcl10, Wdr35, Tnfrsf22 and Tnfrsf23; (iii) the
transcription factor Ankrd1; and (iv) the embryonic myosinMyh3
(Fig. 10d and Supplementary Fig. 12a). Increased expression of
the apoptosis mediator caspase-3 in delACAG muscular tissue
was confirmed by WB, although the levels of its processed active
form varied between mice. Of note, a link between WDR35 and
caspase-3 has been reported25. Overexpression of CDKN1A and
ANKRD1 was corroborated by WB (Fig. 10e and Supplementary
Fig. 12b, c). Two transcripts involved in muscle contraction, Sln
and Nos1, were verified to be markedly up-regulated and down-
regulated, respectively in delACAG mutants. Increased SLN levels
were further proved by WB in the soleus and gastrocnemius of
delACAG mice. Similarly, the amount of triadin (TRDN), which
like SLN, is involved in Ca+2 homeostasis was higher in muscle
extracts from delACAG mutants than in control mice (Fig. 10f
and Supplementary Fig. 12b, c). DelACAG muscles were also
confirmed to have increased expression of the stress-related
myokine Gdf15 and reduced mRNA levels of the inhibitory
myokine of muscle growth myostatin (Mstn). Equivalent qRT-
PCR analysis of dupA mutants revealed a pattern of gene
expression changes similar to delACAG mice, although for most
genes the extent of these changes was lower or not statistically
significant. Finally, we quantified Terc RNA in both exon-15
mutants since it was reported to be stabilized by FXR1P26 and
was absent in our RNAseq assay because lacks poly A tail.
However, no significant differences were detected in the muscle
expression of Terc between control and mutant mice (Fig. 10d
and Supplementary Fig. 12a).
Discussion
Herein, we show that recessive mutations in exon-15 of FXR1 are
associated with a novel multi-minicore myopathy in humans and
mice that varies in severity depending on the consequences of
each mutation. This work also sheds light on the functional
relevance of the evolutionary conserved P82,84 variants in com-
parison to the rest of FXR1P isoforms. Additionally, we
demonstrate that certain FXR1 mutations lead to the synthesis of
abnormal P82,84 proteins which accumulate in a new type of
granular structures inside the cell. DelACAG granules incorpo-
rate mRNA, but are distinct from SGs. Thus, they likely corre-
spond to misfolding and subsequent aggregation of mutant
FXR1P isoforms as described for other proteins in some neuro-
degenerative diseases27.
Fig. 4 Multicore myopathy in mice carrying exon-15 mutations. a Top panel: H-E staining of vastus lateralis cryosections. Arrows designate central nulei
and the arrowhead in delACAG indicates three centralized nuclei. Middle panel: NADH-TR histochemistry of vastus cryosections showing multiple areas
with no enzymatic activity (cores) in delACAG mice and very few in dupA mice. Arrows depict examples of cores. For both panels: n= 7(wt), 9(delACAG),
3(dupA) and scale bars 50 µm. Lower panel: ATPase (pH 4.3) histochemistry in whole soleus cryosections revealing increased type 1 fibers in both
mutants, n= 5(wt), 6(delACAG), 3(dupA). Scale bar 0.5 mm. b Quantification of fiber density (number of fibers/microscope field of view). Graph
represents mean ± s.d. c Minimal Feret’s diameter (MFD, µm) showing relative frequency (%) of different fiber sizes with respect to the total number of
fibers analyzed. Differences in mean MFD between wt and homozygous mutants were statistically significant (wt: 49.8 µm± 12.9 s.d., delACAG: 29.1 µm±
9.9 s.d., dupA: 38.3 µm± 9.7 s.d.). d Percentage of fibers with central nuclei (% CNFs) in wt, delACAG and dupA mice. Graph corresponds to mean ± s.d.
For b–d H-E cryosections of vastus lateralis were used and a total number of n= 455(wt), 1726(delACAG), 465(dupA) fibers were analyzed from 7(wt), 9
(delACAG) and 3(dupA) mice. e Percentage (%) of type I fibers calculated in soleus sections expressed as mean ± s.d. n= 5(wt), 5(delACAG), 3(dupA)
mice. One-way ANOVA (***) with Tukey post-hoc test was used in b and e and Kruskal-Wallis (***) with Dunn’s multiple comparisons test in c and
d. f Representative TEM images of gastrocnemius from wt, delACAG and dupA mice, n= 3(wt), 4(delACAG), 2(dupA) mice. Scale bar 10 µm. Numbers
identify different fibers. Note the variable disorganization of delACAG fibers. Arrows indicate cores. g TEM images of gastrocnemius showing different
defects in delACAG fibers including: large cores (left and middle image. Scale bars 10 µm), central nuclei and abnormal mitochondrial accumulations
(middle image), and Z-line abnormalities including Z-streaming (arrows, right image. Scale bar 2 µm). Arrows in the central picture point to ring-shaped
granules shown in Fig. 7a
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Our data indicate that Myf5-Cre dependent depletion of all
FXR1P isoforms is neonatal lethal, while mice with mutations
exclusively disrupting P82,P84 are viable, even if the dupA/
delACAG mutations are associated with marked reduction of
P82,84 protein levels (dupA), or with abnormal
P82,84 subcellular localization (delACAG). Therefore, we con-
clude that loss of P70-80 FXR1P isoforms, which are
specifically expressed in early myogenic progenitors, accounts for
the lethal phenotype of the Myf5-Cre;Fxr1 conditional
knockouts, while P82,84 are required for maintaining
myofilament alignment and organization of Z-lines. It has
been suggested that similar to the role of FMR1P in neurons,
FXR1P could maintain specific mRNAs in a repressed state in
muscle costamere structures until they are required to be trans-
lated for de novo protein synthesis12. Consistent
with this hypothesis we observed that FXR1P-iso-e is recruited
into SGs which repress translation. Hence, deregulated transla-
tion of specific mRNAs involved in Z-line organization could
underlie the minicore phenotypes resulting from P82,84
mutations.
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Fig. 5 Expression and subcellular localization of P82,84 isoforms in exon-15 mice. a Relative Fxr1 mRNA quantification in gastrocnemius of 2.5-months old
mice by qRT-PCR using two different TaqMan probes: Fxr1-523_m1 (exons 2-3; Mm00484523_m1) and Fxr1-304_m1 (exons 14-15; Mm01286304_m1).
Values are normalized to Tbp mRNA levels and represented as fold change of the mean value of wt mice. n= 6 (wt), 3(delACAG), 3(dupA). Data are
mean ± s.d. followed by one-way ANOVA (***) with Tukey post-hoc test. b Representative FXR1P immunoblot of protein extracts from gastrocnemius
(soluble (SF) and insoluble (IF) fractions) of delACAG and dupA mice and corresponding wt littermates. Vinculin and α-actinin were used as loading
controls (2–3 months old mice, n= 4). Brackets denote isoforms e and f and non-specific bands are labeled with asterisks. c Maximum Z-project and
magnification of confocal anti-FXR1P immunofluorescence images (green) in isolated EDL fibers. n= 8(wt), 3(wt/delACAG), 8(delACAG), 6(dupA). Scale
bars 5 µm. FXR1P isoforms are localized in a striated pattern except in delACAG fibers where are found predominantly in granules. Heterozygous wt/
delACAG fibers contain a small number of granules (arrowheads) and the fluorescent intensity of FXR1P is reduced in dupA mice. Nuclei are labeled with
propidium iodide (PI, red)
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Fig. 6 Co-localization analysis of P82,84 isoforms in EDL fibers. a, b Maximum Z-projects (a) and single slice from Z-stack (b) corresponding to confocal
overlay images of double-immunofluorescence labeling for FXR1P (green) and α-actinin, phalloidin, RYR and COX-IV (red) in isolated EDL fibers from
different mice. Scale bars 5 µm. Arrowheads in panel a point to Z-lines, and in panel b (delACAG COX-IV/FXR1P image) indicate co-localization of FXR1P
granules and mitochondria. Nuclei are stained with DAPI (blue). c Representative RGB intensity profile along a line corresponding to a Z-stack slice of a wt
EDL fiber showing co-localization results between FXR1P (green) and sarcomeric markers (red). FXR1P is adjacent to Z-lines and mitochondria.
Experiments were performed in n= 3 mice except for RYR (n= 2 mice). For each mouse several fibers were analyzed in each experiment
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The phenotype of exon-15 mutant mice indicate that the dupA
mutation is less severe than the delACAG variant which corre-
lates with the different effect of each mutation since: (1) the
amount of FXR1P at Z-lines was significantly lower in delACAG
than in dupA fibers, and (2) only delACAG isoforms accumulated
in distinctive granular structures which interact with mRNA.
Thus, the pathology of delACAG mice not only results from
absence of P82,84 from their normal subcellular localization, but
also from their accumulation in granules which, in addition to
disturb the structure of the fiber, interfere with mRNA trafficking.
Gene expression profiling of delACAG muscle tissue identified
p53 signaling as a main GO/KEGG pathway and revealed
induction of genes related to cell cycle arrest, DNA damage
response, apoptosis and inflammation some of which are p53
targets. The increased levels of Trp73 and Trp63 transcripts in
delACAG mutants are potentially responsible for p53 pathway
activation in these mice as they share functional roles with
p5328,29. Cdkn1a overexpression in delACAG mutants could then
result from p73 induction, or from FXR1P loss-of function since
Cdkn1a mRNA is destabilized by FXR1P26,30,31. Bex1 encodes a
ribonucleoprotein that mediates mRNA stabilization of proin-
flammatory genes including Cxcl1032. The transcript levels of
both Bex1 and Cxcl10 were found increased in delACAG mice,
thus pointing to deregulation of the pro-inflammatory program
in these mice. Notably, a role of FXR1P in controlling abundance
of pro-inflammatory transcripts in vascular smooth muscle cells
has recently been reported33. Several delACAG DEGs are com-
mon to other myopathies. These genes are related to fiber
regeneration, such as Myh3 or to muscle injury and atrophy like
Ankrd1, Gdf15, Mstn or Nos134–36. DelACAG mice were also
a
c d
b
Fig. 7 Ultrastructural evaluation of delACAG granules. a Representative TEM images of granules of different size exclusively observed in gastrocnemius
fibers from delACAG mice. Granules are often located in close proximity to mitochondria. n= 3(wt), 4(delACAG), 2(dupA) mice. Scale bars 2 µm (left
panel), 200 nm (rest of panels). b Representative TEM images of ring-shaped granules from V-4 differentiated myotubes. These structures were not
present in control differentiated myotubes. Multiple myotubes were analyzed. Scale bars 2 µm (left panel), 200 nm (rest of panels). c Anti-FXR1P
immunogold labeling of ultrathin sections from gastrocnemius of delACAG mice showing localization of the mutant protein in the outer electrodense layer
of delACAG granules. n= 3. Scale bar 200 nm. d No-primary antibody control demonstrating no immunogold labeling in granules from delACAG mice.
Scale bar 200 nm
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identified with high levels of both sarcolipin mRNA and protein.
This suggests abnormal Ca+2 handling associated with mutations
in P82,84, since SLN is an inhibitor of SERCA channels, which
pump Ca+2 back from the cytosol to the SR after excitation-
contraction37. Concordantly, approximately 50% of patients with
multi-minicore myopathies are found with recessive mutations in
RYR1 and SEPN1 which are also genes related to Ca+2 home-
ostasis38,39. RYR1 is a Ca+2 channel that allows release of Ca+2
from the SR and SEPN1 regulates RYR140. Additional genes have
been implicated in minicore myopathy. Recessive mutations in
TTN, ACADS, MEGF10, and SECISBP2, dominant mutations in
ACTA1 and MYH7, and one mutation in CCDC78 in a single
family with dominant inheritance have been described in patients
with multi-minicore disease39.
In conclusion, we identified five individuals with neuromus-
cular phenotypes from two unrelated families with different
recessive mutations in the same exon of FXR1. DelACAG mice
reproduced the effect of the human mutation on the protein and
demonstrated pathologic features very similar to those of family 2
patients, specifically muscle atrophy, multicore lesions, central
nuclei and type I fiber predominance. Although patients from
family 2 had neonatal hypotonia and delayed gross motor mile-
stones, the clinical outcome of all three siblings was milder
compared with that observed in patients of family 1. The phe-
notypic differences between delACAG and dupA mice provide
support for the phenotypic variability among patients with dif-
ferent FXR1 mutations. Indeed, similar to dupA mice, which have
milder phenotype than delACAG mutants, no granular accu-
mulations of FXR1P were distinguished in family 2 by TEM
analysis of muscle tissue. Regardless, in addition to possible dif-
ferences in P82,84 expression levels and/or localization between
both families, variable expressivity in monogenic neuromuscular
disorders is common, as seen in the range of phenotypes asso-
ciated with RYR1 mutations41 and among patients with spinal
muscular atrophy42. Considering cardiac muscle, the proband of
family 1 had episodes of tachycardia, but no apparent myocardial
dysfunction was detected in members of family 2. However, since
P82,84 are the main FXR1P isoforms in cardiac muscle, a
potential effect of FXR1-exon-15 mutations in this tissue cannot
be disregarded. The overexpression of proinflammatory pathways
in delACAG mice could contribute to the bone phenotype
observed in these mice since pro-inflammatory cytokines have
adverse effects on BMD43. However, decreased fetal movement,
which often leads to arthrogryposis, hypomineralized bones and
fractures44, is the most likely cause of the bone and arthrogrypotic
phenotype of family 1. The full phenotypic spectrum associated
with FXR1 mutations will continue to expand as more patients
with FXR1-related disorders are recognized.
Methods
Human samples. All patients or patient’s guardians provided written informed
consent to participate in this study and for publication of clinical information,
molecular findings and photographs (Fig. 1). All studies and investigations were
approved by the Medical Research Ethics Committees of the National Research
Centre (Egypt), Hospital La Paz and Consejo Superior de Investigaciones Cientí-
ficas (CSIC) and by the Research Ethics Board of the Hospital for Sick Children
(REB #1000009004). Tissue samples to conduct research were obtained with
appropriate informed consent according to the declaration of Helsinki principles of
medical research involving human subjects.
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Fig. 8 DelACAG granules incorporate mRNA. a, b Confocal images (single Z-slice) of RNA-FISH on EDL isolated myofibers (wt and delACAG) using Cy3-
oligo(dT) (a) or a Cy3-scramble probe (b) in combination with anti-FXR1P immunostaining proving positive oligo (dT) signal in delACAG granules (n= 7).
Scale bar 5 µm. Higher magnifications correspond to the areas designated by arrowheads. Scale bar 2 µm. Nuclei are stained with DAPI
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Genetic analysis. Homozygosity mapping in the proband of family 1 was con-
ducted by whole-genome SNP-array hybridization using CytoSNP-850k BeadChip
SNP-based arrays (Illumina) as indicated in Palencia-Campos et al45. For this
proband WES was provided by Sistemas Genomicos S.L. (Valencia, Spain). Tar-
geted regions were captured using SureSelect Human All Exon Target Enrichment
kit for 51 Mb (Agilent Technologies) and reads were aligned against human gen-
ome assembly GRCh37/hg19. Initial filtering was performed with Picard-tools
(http://broadinstitute.github.io/picard/) and SAM-tools46 and variant calling was
obtained using combination of VarScan47 and GATK48. Identified variants were
annotated using Ensembl database (www.ensembl.org). The filtering pipeline is in
Supplementary Table 1a. SNP-array hybridization in V-4 was performed as in the
proband after biological material became available. Multiplex Ligation-dependent
Probe Amplification (MLPA) of the SMN locus was accomplished using SALSA
probe mix P021 (MRC-Holland) according to the manufacturer specifications. For
WES in family 2 individuals, 2 × 100 bp paired end sequencing was carried out
using the Illumina Hi-Seq 2000 platform after target enrichment of 6.5 µg of
genomic DNA with the Agilent SureSelect Human All Exon 50Mb Capture kit.
Overall mean exon coverage was 177–190X with ≥20X base coverage of 96.7-97.6%.
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Fig. 9 DelACAG granules do not recruit SG components. a, b Representative images of confocal microscopy (single Z-slice) from one-day differentiated V-
4 or control myoblasts treated with or without ARS and co-immunostained for FXR1P and TIAR/RCK or FXR2P. Strong co-localization of FXR1P with TIAR
and FXR2P occurs in amorphous SG granules (arrows), but not in ring-shaped delACAG granules (arrowheads). n= 4(TIAR/RCK), n= 3(FXR2P). Scale
bars 5 µm. c Confocal (Z-project) representative images of transfected HeLa cells with EGFP:FXR1P-iso-e fusion proteins (Supplementary Fig. 10a)
illustrating assembly of the three mutant proteins (delACAG, delA, and dupA) into ring-shaped delACAG-like granules. Equivalent images of transfected
HeLa cells labeled with anti-FXR1P are in Supplementary Fig. 10c. Scale bar 5 µm. Higher magnifications correspond to anti-FXR1P staining of the areas
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Sequence reads were aligned to the reference human genome (hg19/GRCh 37) with
Burrows-Wheeler aligner49 and paired-end duplicate reads were removed (Mark-
Duplicates, Picard tools v.1.35; http://picard.sourceforge.net/). Single nucleotide
variants (SNVs) and insertions/deletions (indels) were detected using GATK
1.1.2850 and annotated using SNPEff (http://snpeff.sourceforge.net/). Data was
analyzed using seqr. Variants were also annotated for frequency in public databases
[1000 genomes; dbSNP135, http://www.ncbi.nlm.nih.gov/projects/SNP/; NHLB1
Exome Sequencing Project (ESP) Exome Variant Server, http://evs.gs.washington.
edu/EVS/]. The potential effect of SNVs were predicted using Polyphen and SIFT.
Array based comparative genomic hybridization (aCGH) in patients from family 2
was conducted in DNA isolated from lymphoblast cell lines (LCL) using an in-
house-designed 8 × 60k genome-wide oligonucleotide custom array with an average
probe spacing of 43 kb (KaryoArray® v3.0; Agilent-based; Agilent Technologies).
Hybridization experiments were performed as recommended by the manufacturer
(Agilent Technologies). Analysis and visualization of Karyoarray® was achieved
with Genomic Workbench Standard Edition 5.0 software (Agilent Technologies).
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Whole-genome SNP-arrays in family 2 were carried out as in family 1 using LCL
genomic DNA.
Cell culture. V-4 primary myoblasts were isolated from a muscle biopsy (quad-
riceps femoris, medial head) and cultured according to a published protocol51.
Briefly, the muscle tissue was mechanically fragmented and incubated at 37 °C/5%
CO2 in 0.2% colagenase I (Sigma)/DMEM for 1 h followed by another incubation
in 0.05% trypsin (Gibco)/ HBSS(Gibco) for 30 min. The digested sample was fil-
tered through a 100 µm nylon cell strainer and plated in 0.2% collagen pre-coated
dishes in growth medium (Ham’s F10+ 20% FBS+ 1% penicillin/streptomycin (P/
S), (Gibco)). In all experiments primary myoblasts from 4–7 passages were used.
Differentiated myotubes were obtained by starving confluent myoblasts (90%) in
differentiation medium (Ham’s F10+ 2% horse serum (HS, Gibco)+ 1% P/S) for
5 days. Human primary fibroblasts were generated from skin biopsy after digesting
the tissue in 0.05% trypsin/PBS for 30 min at 37 °C/5% CO2 and cultured in
DMEM+ 10% FBS+ 1% P/S. Mouse primary myoblasts were obtained from lower
limb muscle packages of 2–3 months old mice. Mouse cells were isolated and
cultured as described for human myoblasts except that were subjected to several
pre-plating steps in non-coated dishes to ensure fibroblast removal. HeLa and
HEK293T were cultured in DMEM+ 10% FBS+ 1% P/S. For SG induction,
myoblasts and transfected HeLa were incubated in 0.5 mM of arsenite (ARS,
Sigma) diluted in the corresponding cell culture media for 45 min before fixation.
For HeLa, the media was refreshed 1 h prior ARS incubation.
Directed mutagenesis, plasmids and transfections. The cDNA of wt FXR1 iso-e
was generated by standard RT-PCR from human muscle mRNA purchased to
Clontech, cloned into pBluescript SK(+) and sequenced. A plasmid containing wt
iso-e sequence (XM_005247813.3) was used as template to create the delACAG,
delA and dupA mutations using the QuikChange II XL Site-Directed Mutagenesis
Kit (Agilent Technologies). Wt and mutant iso-e variants were subsequently
transferred into pEGFP-C1 (Clontech) to generate the corresponding EGFP:
FXR1P-isoe fusion proteins. All constructs were verified by sequencing. HeLa
seeded onto coverslips in 24-well plates were transfected with 500 ng of DNA/well
using Lipofectamine 3000 (Invitrogen) and OptiMEM medium (Gibco). After
5–7 h the media was replaced with DMEM+ 10% FBS+ 1% P/S and 48 h after
transfection, cells were ARS-treated and fixed. HEK293T were transfected by
standard calcium phosphate method and used to corroborate expression of EGFP:
FXR1P-iso-e fusion proteins by WB. HeLa and HEK293T tested negative for
mycoplasma.
Transgenic mice. Fxr1 edited mouse founders were generated by genOway (Lyon,
France). A CRISPR sgRNA specifically designed to target Fxr1 exon15 and generate
the 4-bp ACAG deletion was microinjected into fertilized oocytes. Newborn mice
were screened by PCR and sequence analyzed to assess Fxr1 exon-15 sequence.
Three founders were identified and bred to obtain heterozygous animals. Three
mouse lines were generated, two harboring the 4-bp deletion (delACAG) and one
harboring the adenine duplication (dupA). CRISPR mouse lines were maintained
independently in a C57BL/6 J genetic background by crossing heterozygous males
to wt females. Heterozygous offspring from these crosses were mated to generate
homozygous mutants and control mice for experimental purposes. Homozygous
mutants from both independent delACAG lines were analyzed and confirmed to
produce identical results. Experiments were performed using homozygous mutants
and control wt mice offspring of F2 to F5 heterozygous crosses without finding any
difference in phenotypes. Studies with conditional knockout mice were carried out
in a C57BL/6 J background. Fxr1 floxed mice13 and Myf5-Cre transgenics16 were
previously reported. Tg.CAG-Cre deleter mice were used to achieve constitutive
global excision of Fxr1 exon-1. Experiments involving mice were performed
according to ethical regulations and were approved by the corresponding Ethics
committees of Instituto de Investigaciones Biomédicas “Alberto Sols” and CSIC.
Histopathology. Vastus lateralis, gastrocnemius and soleus of 3 month old female
mice were dissected, embedded together in OCT, and frozen by submersing in
isopentane pre-cooled in liquid nitrogen. Transverse cryostat sections (10 µm)
containing the three muscles were stained with haematoxylin-eosin (H-E) or used
for NADH-TR and ATPase 4.3 enzymatic histochemistry following standard
procedures. Pictures were captured with a Zeiss Axiophot microscope. H-E cross-
sections of vastus were used to quantify cell number/microscope field of view
(375.56 × 282.78 µm2), cell size (minimal Feret’s diameter: MFD) and the percen-
tage of fibers with central nuclei. For each mouse, 3 independent images from the
same cryosection were counted. Relative frequency of MFD (%) was determined
using length intervals of 5 µm. Quantification of type 1 fibers using ATPase (pH
4.3) histochemistry was conducted in an entire cross-section of soleus. For histo-
pathological analysis of family 2, a muscle biopsy of the right triceps was performed
from II-4. Biopsy portions were fixed in formalin for light microscopy, and snap
frozen for histochemistry and immunohistochemistry. Using standard histo-
chemical protocols, cryostat sections were processed for H-E, modified Gomori
trichrome, Masson trichrome staining, Periodic acid Schiff, oxidative enzymes, Oil
red O, Congo Red, and ATPase at pH 9.4 and 4.3. Samples for TEM were fixed and
processed according to standard protocol.
Electron microscopy of mouse tissue and differentiated myotubes. Gastro-
cnemius specimens of 3 month old female mice were fixed in 1% glutaraldehyde/
4% PFA in 0.1 M cacodilate buffer overnight, postfixed in 1% osmium tetroxide in
water for 60 min and dehydrated through a series of ethanol solutions and acetone.
After the last dehydration step, samples were incubated in a 1:3, 1:1, 3:1 mixture of
durcupan resin and acetone and cured at 60 °C for 48 h. Longitudinal ultrathin
sections (50–60 nm) were obtained with a diamond knife (Diatome) in an ultra-
microtome (Leica Reichert ultracut S) and collected in 200-mesh copper grids.
Sections were counterstained with 2% uranyl acetate in water for 20 min followed
by a 10 min incubation step with a lead citrate solution. Samples were examined
with a JEOL JEM1010 electron microscope (Jeol Ltd., Tokyo, Japan). For ultra-
structural analysis of cultured myotubes, myoblasts were seeded and differentiated
in Permanox plastic chamber slides (Lab-Tek) and subsequently fixed and
embedded as described above except that acetone was not included in the dehy-
dration steps. Myotubes were embedded in Epon resin, sectioned and counter-
stained as indicated for muscle tissue.
Immunogold labeling. Immunogold staining was performed in samples from
gastrocnemius of delACAG and control mice fixed in 0.25% glutaraldehyde/4%
PFA in phosphate buffer 0.1 M, dehydrated and embedded in LR White resin.
Ultrathin sections of 60 nm collected in 200-mesh Ni grids were blocked and
incubated with anti-FXR1P (Proteintech; 1:100) and corresponding secondary
antibody (Aurion, 10 nm gold conjugate goat anti-rabbit; 1:30) according to the
post-embedding immunogold protocol recommended by the manufacturer (Aur-
ion). Samples were postfixed in 2% glutaraldehyde/PBS and contrasted with 2%
uranyl acetate/H20.
Magnetic resonance imaging (MRI). MRI examination of mice was performed in
14 weeks old female mice in a 7.0 T 16 cm bore Bruker Biospect (Bruker Medical
Gmbh, Ettlingen, Germany). Mice were maintained anesthetized with 1–2% iso-
flurane in 1 L of oxygen through the experiment. T2-weighted spin echo anato-
mical images were acquired with a rapid acquisition with relaxation enhancement
sequence in axial and coronal orientations with the following parameters: TR=
3000 ms, TE= 11.57 ms, RARE factor= 8, Av= 12, FOV= 2.5 cm, acquisition
matrix= 256 × 256 corresponding to an in plane resolution of 97 × 97μm2, slice
thickness= 1 mm without gap between slices. To calculate muscle volume, the
muscular area was measured in 5 consecutive slices of hindlimbs, starting at 2 slices
after tibial plateau in each mouse. Muscle volume value was the mean of both
hindlimbs. Human muscle MRI for II-5 (family 2) was performed of both upper
and lower proximal muscles utilizing axial and coronal Short-TI Inversion
Recovery (STIR) and T1-weighted images.
Dual-energy x-ray absorptiometry (DXA) and X-rays. Bone mineral density
(BMD, g·cm−2) was assessed in 4-month old anesthetized female mice by dual-
energy X-ray absorptiometry using PIXImus (GE Lunar Corp., Madison, WI, USA)
as previously explained52. This parameter was measured in the selected ROI
Fig. 10 Gene expression profiling in skeletal muscle from delACAG mutants. a Hierarchical clustering and heatmap visualization of RNA-seq data (selected
DEGs) resulting from analysis of skeletal muscle RNA samples isolated from 3 wt and 3 delACAG P15 mice. b Number of genes upregulated (red) and
downregulated (green) among selected 233 DEGs. c Gene Ontology (GO) term enrichment analysis showing pathways and biological processes over-
represented in selected DEGs. Gene count is shown on the X-axis (Supplementary Table 3a). d Relative expression analysis of the indicated genes by qRT-
PCR using TaqMan expression assays in gastrocnemius RNA of 1.5-months old mice. Values are normalized to Tbp expression and are represented as fold
change of the mean value of wt expression. Graphs are mean ± s.d. followed by one-way ANOVA with Tukey post-hoc test. n= 3. e Representative
immunoblots showing protein levels of CDKN1A, ANKRD1, CASP3 and cleaved CASP3 in gastrocnemius from 2–3-months old delACAG and dupA mice
and corresponding wt littermates. f Representative immunoblots for SLN and TRDN in protein extracts from the soleus (SLN) or gastrocnemius (TRDN)
from delACAG, dupA and wt mice demonstrating increased expression of both proteins in delACAG mutants.Vinculin served as loading control in e and
f. n= 6(wt), 3(delACAG), 3(dupA) mice for all proteins excepting SLN (n= 7(wt), 4(delACAG), 3(dupA) mice)
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(region of interest, cm2) in vertebrae L4–L5 (35 × 23 pixels) and femur (11 × 33 and
17 × 13 pixels), defining trabecular and cortical bone values, respectively. For X-
rays fore-limbs and hind-limbs of 3.5 or 4-months female mice were dissected and
stripped of muscle tissue prior to be analyzed. In each independent experiment the
limbs of all genotypes were X-rayed simultaneously on the same film using a HP
Faxitron 43855A instrument with 12 KV intensity for 10 s. Films were subsequently
photographed. Mice of the same age were used in each experiment.
Functional performance tests. Muscular strength and endurance were assessed in
14-weeks-old female mice using three different tests: rotarod, weight test and
hanging wire test. Rotarod fatigue assay was conducted using a 47600 Rotarod
Instrument (Ugo Basile, Italy) following the protocol published by Carrell EM
et al.53. For the weight test we created 5 different weights, consisting of a 7 g ball of
metallic thread (0.33 mm thickness) to which we attached a 1–5 steel chain links
each weighting 12 g. Final weights: 19, 31, 43, 55, and 67 g. The weight test was
carried out as explained by Deacon RM54 and was repeated three consecutive days
in each mouse. Scores were calculated as mean ± s.d. per animal. The hanging wire
test was performed according to standardized operating procedure described by
Maaike van Putten et al. (TREAT-NMD, Neuromuscular Network, http://www.
treat-nmd.eu/resources/research-resources/dmd-sops/, 2016) using the falls and
reaches-method. In addition to the falling and reaching scores we introduced a new
score that we named “four limbs” based on the number of times that the mouse was
able to lift both hindlimbs and grabbed the wire with all four extremities. This score
starts from zero and increases by 1 each time that an event of this type occurs in a
total of 180 s and until a maximum score of 10.
Immunoblotting. Muscle tissues were homogenized using a T10 basic ULTRA-
Turrax (IKA) in RIPA lysis buffer (150 mM NaCl, 50 mM TrisHCl, 2 mM EDTA,
0.5% Sodium Deoxicolate, 0.1% SDS, 1% NP-40) supplemented with protease
inhibitors (Sigma P8340, 1 mM PMSF) and phosphatase inhibitors (Sigma P0044
and P5726, 1 mM Na3O4V and 10 mM NaF). Following a 20 min incubation step at
4 °C, the tissue homogenate was sonicated in a cold bath at max power for 1 min,
and clarified by centrifugation at 4 °C (15 min, 14000×g). Supernatants were col-
lected and considered as the soluble fraction (SF), and the pellets (insoluble frac-
tion, IF) were re-dissolved for 30 min in 8M urea in the presence of protease and
phosphatase inhibitors and subsequently sonicated (3 cycles of 1 min). Protein
quantification was conducted with BCA Protein Assay (Pierce). Protein samples
(40 µg) were separated by SDS-PAGE, transferred onto nitrocellulose membranes
and subjected to WB. Embryonic tissue homogenates and cultured cell lysates were
obtained in RIPA buffer following the procedure indicated for muscle tissue. The IF
fraction of cultured myoblasts and myotubes was extracted in urea, as explained
above. Primary antibodies: FXR1P all isoforms (Proteintech, 13194-1-AP, 1:4000;
#ML1355 serum 1:10000), FXR1P iso-e/f-specific (#27-15 and #27-17 policlonal
sera, 1:4000)5, α-actinin (Millipore 05-384, 1:4000), MHC (R&D systems
MAB4470, 1:10000), α-tubulin (Sigma T9026, 1:20000), vinculin (Santa Cruz sc-
73614, 1:1000), caspase-3 (Cell Signaling #9665, 1:1000,), cleaved (active) caspase-3
(Cell Signaling #9661, 1:500), CDK1NA (Santa Cruz sc-397, 1:500), ANKRD1
(Proteintech 11427-1-AP, 1:1000), triadin (Thermofisher MA3-927, 1:1000), SLN
(1:100)56, and GFP (Santa Cruz sc-9996, 1:1000). HRP-conjugated secondary
antibodies were from Jackson ImmunoResearch. WB were developed using ECL
reagent (Amersham). Anti-FXR1P antibodies Proteintech 13194-1-AP and #27-15
were demonstrated to recognize FXR1P isoforms using cells transfected with EGFP:
FXR1-iso-e isoforms (Supplementary Fig. 10). Uncropped scans of WBs are pre-
sented in Supplementary Fig. 13.
Isolation of EDL fibers and confocal microscopy. Dissected EDL muscles were
digested in 0.2% collagenase type I (Sigma)/DMEM for 1 h at 37 °C/5% CO2 and
subsequently transferred to HS pre-coated Petri dishes containing fresh DMEM+
1% P/S to release myofibers with the help of gentle flushing as described by Pasut
et al.57. For immunoanalysis, isolated EDL fibers were plated in chamber slides
(Lab-Tek) precoated with 3% matrigel and incubated in DMEM+ 2%HS+ 1% P/S
for 2 h before being fixed in pre-warmed 4% PFA/PBS for 5 min at room tem-
perature. Fibers were next permeabilized in 0.5% Triton X-100/PBS for 10 min,
blocked in 4% goat serum/0.1% Triton X-100/PBS for 30 min and incubated with
primary antibodies diluted in blocking solution overnight at 4 °C. After several
washes with 0.1% Triton X-100/PBS the corresponding secondary antibodies
(Molecular Probes) and/or Phalloidin-546 (Molecular Probes A22283, 1:200) were
applied for 1 h at room temperature. Nuclei were stained with DAPI (1:1000 in
PBS) or propidium iodide (Sigma-Aldrich; 20 µg·ml−1 in 0.05% Tween-PBS).
Chamber slides were mounted with Prolong Diamond. Myoblasts, differentiated
myotubes and HeLa were grown in coverslips, fixed in 4% PFA/PBS for 10 min,
permeabilized with 0.1% Triton X-100/PBS for 15 min and blocked in 4% serum/
PBS-0.05% Triton X-100 for 30 min. Cells were incubated with primary antibody
overnight 4 °C, washed 3 times with 0.05% Tween/PBS and then incubated with
fluorescently labeled secondary antibodies (Molecular Probes) for 1 h, washed and
DAPI stained before being mounted with Prolong Diamond. Primary antibodies:
FXR1P (Proteintech 13194-1-AP, 1:200), α-actinin (Millipore 05-384, 1:200), RYR
(Abcam ab2868, 1:200), COX-IV (Invitrogen 459600, 1:200), desmin (Abcam
ab6322, 1:100), MHC (R&D MAB4470, 1:2000), TIAR (Santa Cruz sc-1749, 1:30),
FXR2P (Santa Cruz sc-32266 1:60), FMR1P (DSHB 7G1-1, 1:70), RCK (Santa Cruz
sc-376433, 1:30). Fluorescence images were acquired with a Leica SP5 confocal
microscope or Zeiss LSM710.
RNA-FISH. Isolated EDL fibers were fixed in 4% PFA (10 min) and permeabilized
in 0.5% Triton X-100/PBS (30 min). Subsequently, fibers were incubated in pre-
hybridization buffer (30% formamide, 2xSSC) for 10 min at room temperature and
hybridized for 2 h at 37 °C with 1 ng·µl−1 of Cy3-labeled oligonucleotide probe in
hybridization buffer (30% formamide, 10% dextran sulfate, 1 mg·ml−1 yeast tRNA,
2xSSC, 2 mM vanadyl complex, 0.005% BSA). Poly(A)+ mRNAs were detected
using a 5′-Cy3 labeled oligo-(dT)30, and a previously published 5′-Cy3-tagged
scrambled oligonucleotide (5′-TGTAACACGTCTATACGCCCA-3′)19 was used as
negative control. Following hybridization, fibers were washed in 30% formamide 4x
SSC (20 min), 4xSSC (20 min), 2xSSC (20 min) before immunolabelling. Anti-
FXR1P (Proteintech 1:200) and secondary antibody (1:1000) were diluted in 0.1%
Triton X-100/2xSSC and subsequent washes were performed in 2xSSC. Fibers were
stained with DAPI, mounted with Prolong and evaluated by confocal microscopy.
The same procedure was applied for human cultured differentiated myotubes.
Transcriptomics. For RNAseq, 6 RNA samples corresponding to 3 wt and 3
delACAG mice were used. RNA samples were isolated from gastrocnemius and
soleus of P15 mice using TriReagent solution (Ambion) according to the manu-
facturer protocol. Library generation and RNA sequencing were performed at
Sistemas Genómicos S.L. (Valencia, Spain). Ribosomal RNA was removed with the
Ribo-Zero rRNA removal kit (Illumina) and generation of index-tagged cDNA
libraries was performed with the TruSeq Stranded Total RNA library Prep kit from
2 μg of total RNA. Sequencing was conducted in a HiSeq2500 instrument (Illu-
mina) and sequencing readings were paired-end with a length of 101 bp. Estimated
coverage was around 52 million reads per sample. Quality control of the raw data
was assessed using the FastQC v0.11.4 tool and the raw paired-end reads were
mapped against the mouse genome provided by Ensembl database (GRCm38)
using Tophat2 2.1.0 algorithm58. Insufficient quality reads (phred score <5) were
eliminated using Samtools 1.246 and Picard Tools 2.12.1. The differential expres-
sion analysis between wt and delACAG samples was conducted using statistical
packages designed by Python and R. Expression levels were calculated using the
HTSeq59 and differential expression analysis between conditions was assessed
using DESeq260 applying a differential negative binomial distribution for the sta-
tistics significance61. We selected differentially expressed genes with a P value
adjusted by FDR61 ≤ 0.05 and fold change value below −1.9 or higher than 1.9 to
avoid identification of false positives across the differential expression data. For
Gene Set functional enrichment analysis and network analysis, differentially
expressed sets were processed using ClusterProfiler62, a Bioconductor package to
search for biological processes involved. This tool screens for genes in specific
databases (Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes
(KEGG)) to evaluate biological annotations that rise as over-represented with
respect to the whole genome.
qRT-PCR. Gastrocnemius from age-matched normal and mutant mice were dis-
sected and maintained in RNAlater (Ambion) until processing. The tissue was
homogenized and RNA extracted with TriReagent solution according to the
manufacturer’s protocol. cDNA was synthetized from 250 ng of total RNA with
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) using ran-
dom primers. Quantitative RT-PCR was performed in a 7900HT Fast Real-Time
PCR System (Applied Biosystems) using TaqMan real-time PCR gene expression
assays (Applied Biosystems). For each TaqMan assay three mice per genotype were
analyzed and every sample was run in triplicates. Transcripts levels were nor-
malized against expression of housekeeping genes (Tbp, Gusb, β2M). Fold differ-
ences were calculated by the 2−ΔΔCt method using as calibrator sample the mean
value of wt mice. The following assays were used: Fxr1 (exons 2–3;
Mm00484523_m1), Fxr1 (exons 14–15; Mm01286304_m1), Trp53 (exons 1–2;
Mm01731287_m1), Trp53 (exons 9–10 Mm01337166_mH), Trp63
(Mm00495788_m1), Trp73 (Mm00660220_m1), 4930567H12Rik (Cdkn1a,
Mm00432448_m1), Rb1 (Mm01310562_m1), Nfkb2 (Mm00479807_m1), Eda2r
(Mm01236761_m1), Tnfrsf22 (Mm00445826_m1), Tnfrsf23 (Mm00656375_m1),
Bex1 (Mm00784371_s1), Cxcl10 (Mm00445235_m1), Wdr35 (Mm00552654_m1),
Ankrd1 (Mm00496512_m1), Gdf15 (Mm00442228_m1), Myh3
(Mm01332463_m1), Sln (Mm00481536_m1), Terc (Mm01261365_s1), Nos1
(Mm01208059_m1), Mstn (Mm01254559_m1), Tbp (Mm00446973_m1), Gusb
(Mm01197698_m1) and β2M (Mm00437762_m1). For TaqMan assays capable to
detect DNA (Cdkn1a, Bex1, and Terc), RNA samples were treated with Turbo-
DNA-free Kit (ThermoFisher) to eliminate possible residual DNA contamination.
For Fxr1 expression analysis, 2.5 month old mice were used and for the rest of
genes RNA was obtained from mice of 1.5 months of age.
Image and statistical analyses. Statistical analysis was conducted with GraphPad
software. D’Agostino-Pearson, Shapiro-Wilk, Kolmogorov-Smirnov normality tests
or Skewness and kurtosis normality score were used to assess normal distribution
of data. Variance F-test, Brown-Forsythe or Bartlett’s tests were used to test
homoscedasticity of variance. Parametric tests including one-way ANOVA with
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Tukey’s multiple comparisons test or two-tailed unpaired Student’s t-test were used
after validation of normality and homoscedasticity of variance. When normality
was not assumed non-parametric Kruskal-Wallis with Dunn’s multiple comparison
test as post-hoc was used. No randomization, predetermination of sample size or
blinding was used. P-values ≥ 0.05 were considered statistically non-significant;
***P < 0.001; **P < 0.01; *P < 0.05. Image analysis, quantifications and WB densi-
tometry were conducted with Image J-Fiji software.
Data availability
The RNA-Seq data from this study has been deposited in NCBI Sequence Read Archive
(SRA) database with accession number SRP150400.
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